Effect of sertraline on plasma nortriptyline levels in depressed elderly

Journal of Clinical Psychiatry

Volumn 58, Issue 10, 1997, Pages 440-443

  Solai, Lalithkumar K ^a   Mulsant, Benoit H ^a,c   Pollock, Bruce G ^a   Sweet, Robert A ^a   Rosen, Jules ^a   Yu, Kai ^b   Reynolds III, Charles F ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NORTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DATA BASE; DEPRESSION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; ELDERLY CARE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL;

EID: 0030656608     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v58n1006     Document Type: Article

References (29)

1. Seth R, Jennings AL, Bindman J, et al. Combination treatment with noradrenalin and serotonin reuptake inhibitors in resistant depression. Br J Psychiatry 1992;161:562-565
2. Taylor D. Selective serotonin reuptake inhibitors and tricyclic antidepressants in combination: interactions and therapeutic uses. Br J Psychiatry 1995;167:575-580
3. Weilburg JB, Rosenbaum JF, Biederman J, et al. Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. J Clin Psychiatry 1989;50:447-449
4. Cavanaugh SA. Drug-drug interactions of fluoxetine with tricyclics. Psychosomatics 1990;31:273-276
5. DeVane CL. Pharmacogenetics and drug metabolism of newer antidepressant agents. J Clin Psychiatry 1994;55:38-45
6. Ereshefsky L, Riesenman C, Lam YW. Antidepressant drug interaction and the P450 system: the role of cytochrome P450 2D6. Clin Pharmaco-kinet 1995;29:10-18
7. Pollock BG. Recent developments in drug metabolism of relevance to psychiatrists. Harv Rev Psychiatry 1994;4:204-213
8. Dahl ML, Bertilsson L, Nordin C. Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype. Psychopharmacology 1996;123:315-319
9. Preskom SH. Introduction. Reducing the risk of drug-drug interactions: a goal of rational drug development. J Clin Psychiatry 1996;57(suppl 1):3-6
10. Mulsant BH, Foglia JP, Sweet RA, et al. The effect of perphenazine on the concentration of nortriptyline and its hydroxymetabolites in older patients. J Clin Psychopharmacol 1997;17:318-320
11. Pollock BG, Mulsant BH. Antipsychotics in older patients: a safety perspective. Drugs Aging 1995;6:312-323
12. Harvey AT, Preskorn SH. Interactions of serotonin reuptake inhibitors with tricyclic antidepressants. Arch Gen Psychiatry 1995;52:783-784
13. Jeppesen U, Gram LF, Vistisen K, et al. Dose-dependent inhibition of CYP1A2, CYP2C19, and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996;51:73-78
14. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153:311-320
15. Popli AH, Baldessarini RJ, Cole JO. Interactions of serotonin reuptake inhibitors with tricyclic antidepressants. Arch Gen Psychiatry 1994;51: 666-667
16. Crewe HK, Lennard MS, Tucker GT, et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-265
17. von Moltke L, Greenblatt DJ, Harmatz JS, et al. In vitro inhibition of desipramine (DMI) oxidation by fluoxetine (F) and norfluoxetine (NF) is greater than inhibition by sertraline (S) or desmethylsertraline (DS) [abstract]. Clin Pharmacol Ther 1993;53:198
18. Alderman J, Greenblatt DJ, Allison J, et al. Desipramine pharmacokinetics with the selective serotonin reuptake inhibitors, paroxetine or sertraline. Presented at the 147th annual meeting of the American Psychiatric Association; May 22-26, 1994; Philadelphia, Pa
19. Preskorn SH, Alderman J, Chung M, et al. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 1994;14:90-98
20. Mulsant BH, Pollock BG, Rosen J. Newer antidepressants and antipsychotics in geriatric psychiatry. Nursing Home Medicine 1997;5:247-257
21. Oxman TE. Antidepressants and cognitive impairment in the elderly. J Clin Psychiatry 1996;57(suppl 5):38-44. Correction 1996;57:374
22. Gram LF, Brosen K, Kragh-Sorensen P, et al. Steady-state plasma levels of E- and Z-10-OH-nortriptyline in nortriptyline patients: significance of concurrent medication and the sparteine oxidation phenotype. Ther Drug Monit 1989;11:508-514
23. Mellstrom B, Bertilsson L, Sawe J, et al. E- and Z-10-OH-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther 1981;30:189-193
24. Sproule BA, Otton SV, Cheung SW, et al. CYP2D6 inhibition in patients treated with sertraline. J Clin Psychopharmacol 1997;17:102-106
25. Barros J, Asnis G. An interaction of sertraline and desipramine [letter]. Am J Psychiatry 1993;150:1751
26. Kurtz D, Bergstrom R, Goldberg M, et al. Drug interaction between sertraline and desipramine or imipramine [abstract]. J Clin Pharmacol 1994;34: 1030
27. Lydiard RB, Anton RF, Cunningham T. Interactions between sertraline and tricyclic antidepressants. Am J Psychiatry 1993;150:1125-1126
28. Preskorn SH. Drug-drug interactions [letter with reply]. J Clin Psychiatry 1996;57:223-225
29. Pollock BG, Perel JM. Tricyclic antidepressants: contemporary issues for therapeutic practice. Can J Psychiatry 1989;34:609-617